Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
Intratracheal and subcutaneous liposomal VIP normalizes arterial pressure in spontaneously hypertensive hamsters.
复制标题
气管内和皮下脂质体 VIP 可使自发性高血压仓鼠的动脉压正常化。
DOI：
10.1016/j.ijpharm.2006.02.028
复制
发表时间：
2006
影响因子：
5.8
通讯作者：
Onyüksel,Hayat
中科院分区：
文献类型：
--
作者：
Rubinstein,Israel;Ikezaki,Hiroyuki;Onyüksel,Hayat
我们确定了单次气管内和皮下施用生物相容性和可生物降解的血管活性肠肽与空间稳定脂质体自相关（VIP-SSL）是否可以使自发性高血压仓鼠（SHH）的平均动脉压（MAP）正常化。我们发现通过任一途径施用 VIP-SSL (0.1nmol) 可使 MAP 正常化 (p<0.05)。 10-20分钟内观察到最大效果并持续6小时。 VIP-SSL 对心率没有显着影响。单独的 VIP (0.1nmol) 和空 SSL 对 MAP 没有显着影响。 VIP-SSL (0.1nmol) 对年龄/基因匹配的对照仓鼠的 MAP 和心率没有显着影响。鉴于这些数据，我们建议应进一步开发 VIP-SSL 的肺部和皮下递送作为治疗原发性高血压的肽纳米药物。
We determined whether a single intratracheal and subcutaneous administration of biocompatible and biodegradable vasoactive intestinal peptide self-associated with sterically stabilized liposomes (VIP-SSL) normalizes mean arterial pressure (MAP) in spontaneously hypertensive hamsters (SHH). We found that VIP-SSL (0.1nmol) administered by either routes normalizes MAP (p<0.05). Maximal effect was observed within 10–20min and lasted for 6h. VIP-SSL had no significant effects on heart rate. VIP alone (0.1nmol) and empty SSL had no significant effects on MAP. VIP-SSL (0.1nmol) had no significant effects on MAP and heart rate in age/genetically-matched control hamsters. Given these data, we suggest that pulmonary and subcutaneous delivery of VIP-SSL should be further developed as peptide nanomedicine for essential hypertension.